FinnGen Welcomes Bayer as a New Industry Partner
With the addition of Bayer to its line-up of international industry partners, FinnGen continues on its mission to explore genetic data using advanced analytics to better understand diseases and improve treatments. The collaboration highlights the growing commitment of the biopharmaceutical industry in supporting genomic initiatives that drive groundbreaking research, aiming to improve health care globally.
“We are thrilled to welcome Bayer into the FinnGen consortium,” says Aarno Palotie, the Scientific Director of the FinnGen Study. “Their expertise of the Nordic healthcare ecosystem and Bayer's dedication to advancing pharmaceutical R&D in Finland will play an important role in our scientific mission to uncover valuable insights into the genetic causes of disease.”
FinnGen leverages its unique combination of genetic data from Finnish biobank sample donors and national health register data to provide a powerful resource for researchers worldwide. The project, now in its third phase, has contributed to significant advancements in identifying genetic risk factors for common and rare diseases, benefiting from the contributions of both its academic and industry partners.
The collaboration will further strengthen FinnGen’s existing consortium which brings together thirteen international pharmaceutical companies and all relevant Finnish public stakeholders.
Bayer is dedicated to advancing research and development to drive innovation in healthcare and improve patient outcomes worldwide. As a key player in the Finnish life science innovation ecosystem with significant annual investments and a strong presence, Bayer collaborates extensively with universities, research institutes and companies.
The FinnGen collaboration will enhance data-driven research in Finland and promote the emergence of new globally significant pharmaceutical innovations.
"Combining clinical and genomic data is critical for generating scientific insights that aid in understanding illness development and developing novel therapeutics. Bayer is thrilled to be a part of the FinnGen initiative, as it will allow us to interact with a worldwide scientific network and receive access to vital research insights," says Sai Jasti, SVP, Head of Data Science and AI at Bayer Pharma Global R&D.